Pharsight

Zepbound patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(6 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(7 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(15 years from now)

Zepbound is owned by Eli Lilly And Co.

Zepbound contains Tirzepatide.

Zepbound has a total of 4 drug patents out of which 0 drug patents have expired.

Zepbound was authorised for market use on 28 March, 2024.

Zepbound is available in solution;subcutaneous dosage forms.

Drug patent challenges can be filed against Zepbound from 13 May, 2026.

The generics of Zepbound are possible to be released after 14 June, 2039.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 08, 2026
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ZEPBOUND family patents

Family Patents